AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21936254 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopically-assisted repair
Number of subjects: 44
Study 21936254 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 44
Study 16034556 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day contingent payment for smoking abstinence (14C)
Number of subjects: 63
Study 16034556 — intervention group
Group type: COMPARATOR
Intervention: 7-day contingent payment for smoking abstinence (7C)
Number of subjects: 63
Study 16034556 — intervention group
Group type: COMPARATOR
Intervention: 1-day contingent payment for smoking abstinence (1C)
Number of subjects: 63
Study 12127203 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex (DVPX)
Number of subjects: 0
Study 12127203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9772311 — intervention group
Group type: EXPERIMENTAL
Intervention: Avaxim
Number of subjects: 185
Study 9772311 — intervention group
Group type: COMPARATOR
Intervention: Havrix
Number of subjects: 185
Study 8027937 — intervention group
Group type: EXPERIMENTAL
Intervention: TempaDOT
Number of subjects: 502
Study 8027937 — intervention group
Group type: COMPARATOR
Intervention: IVAC
Number of subjects: 502
Study 8027937 — intervention group
Group type: COMPARATOR
Intervention: off-the-shelf glass
Number of subjects: 502
Study 3140592 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergocristine (10 mg capsules, twice a day for 5 days, then 3 times a day for 5 days if treatment failed)
Number of subjects: 30
Study 3140592 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine (2.5 mg capsules, twice a day for 5 days, then 3 times a day for 5 days if treatment failed)
Number of subjects: 30
Study 30075534 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 226
Study 30075534 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 226
Study 30075534 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg and 10 mg BID
Number of subjects: 226
Study 30075534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study 28583732 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Negative Pressure (TNP) therapy
Number of subjects: 22
Study 28583732 — intervention group
Group type: COMPARATOR
Intervention: Control (regular topical dressings)
Number of subjects: 22
Study 26125448 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib (AZD6244, ARRY‐142886) + docetaxel
Number of subjects: 0
Study 26125448 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel alone
Number of subjects: 0
Study 23095760 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate left ventricular hypertrophy (LVM(inappr))
Number of subjects: 626
Study 23095760 — intervention group
Group type: EXPERIMENTAL
Intervention: LVM(inappr)
Number of subjects: 626
Study 23095760 — intervention group
Group type: COMPARATOR
Intervention: LVM or LVMI
Number of subjects: 626
Study 20350029 — intervention group
Group type: EXPERIMENTAL
Intervention: unsupported online CCBT
Number of subjects: 303
Study 20350029 — intervention group
Group type: EXPERIMENTAL
Intervention: CCBT&TAU
Number of subjects: 303
Study 20350029 — intervention group
Group type: COMPARATOR
Intervention: CCBT, TAU, CCBT&TAU
Number of subjects: 303
Study 18253905 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose solution
Number of subjects: 174
Study 18253905 — intervention group
Group type: COMPARATOR
Intervention: Sodium hyaluronate (SHA)
Number of subjects: 174
Study 17175820 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (100 mg every 8 hours)
Number of subjects: 45
Study 17175820 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (400 mg every 8 hours)
Number of subjects: 45
Study 17175820 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined analgesic (50 mg tramadol every 8 hours and 200 mg ibuprofen every 8 hours)
Number of subjects: 45
Study 15015908 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy treatment (n=6, n=5)
Number of subjects: 15
Study 15015908 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (n=4)
Number of subjects: 15
Study 10971455 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of melatonin orally during oestradiol replacement
Number of subjects: 14
Study 10971455 — intervention group
Group type: COMPARATOR
Intervention: Placebo during oestradiol replacement
Number of subjects: 14
Study 8839900 — intervention group
Group type: EXPERIMENTAL
Intervention: Fadrozole, 1 mg twice daily
Number of subjects: 80
Study 8839900 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen, 20 mg daily
Number of subjects: 80
Study 1531483 — intervention group
Group type: EXPERIMENTAL
Intervention: Fadrozole 4 mg daily for 14 days
Number of subjects: 8
Study 6829674 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 burns administered over one half the trabecular meshwork (Group 1)
Number of subjects: 40
Study 6829674 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 burns administered over the entire trabecular meshwork (Group 2)
Number of subjects: 40
Study 31321524 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG)
Number of subjects: 70
Study 31321524 — intervention group
Group type: COMPARATOR
Intervention: Sennosides
Number of subjects: 70
Study 28917689 — intervention group
Group type: EXPERIMENTAL
Intervention: Early statin group (pitavastatin 4 mg/day from baseline)
Number of subjects: 53
Study 28917689 — intervention group
Group type: COMPARATOR
Intervention: Late statin group (pitavastatin 4 mg/day from 3 weeks after baseline)
Number of subjects: 53
Study 28917689 — intervention group
Group type: EXPERIMENTAL
Intervention: Early statin group
Number of subjects: 53
Study 28917689 — intervention group
Group type: COMPARATOR
Intervention: Late statin group
Number of subjects: 53
Study 28917689 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 53
Study 27264216 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial Fibrillation Decision Support Tool (AFDST)
Number of subjects: 1493
Study 27264216 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1493
Study 25418492 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of Candesartan (32 mg)
Number of subjects: 69
Study 25418492 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional doses of Candesartan (16 mg)
Number of subjects: 69
Study 25418492 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive treatment other than ARBs or angiotensin-converting enzyme inhibitors (Control group)
Number of subjects: 69
Study 23020199 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years (IY) parent and child interventions for 6 months
Number of subjects: 49
Study 21169164 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal e-mental health intervention with manualized telephone support
Number of subjects: 21
Study 21169164 — intervention group
Group type: COMPARATOR
Intervention: Control group not applicable (single arm trial)
Number of subjects: 21
Study 19043945 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymyxin B sulfate/trimethoprim, 1 drop four times daily for 7 days
Number of subjects: 56
Study 19043945 — intervention group
Group type: COMPARATOR
Intervention: 0.5% Moxifloxacin, 1 drop three times daily for 7 days
Number of subjects: 56
Study 16402597 — intervention group
Group type: EXPERIMENTAL
Intervention: Point process adaptive filter algorithm applied to simulated heartbeat data
Number of subjects: 0
Study 16402597 — intervention group
Group type: EXPERIMENTAL
Intervention: Point process adaptive filter algorithm applied to actual heartbeat data from a tilt table experiment
Number of subjects: 0
Study 16402597 — intervention group
Group type: EXPERIMENTAL
Intervention: Point process adaptive filter algorithm applied to actual heartbeat data from healthy subjects
Number of subjects: 0
Study 16402597 — intervention group
Group type: EXPERIMENTAL
Intervention: Point process adaptive filter algorithm applied to actual heartbeat data from subjects with congestive heart failure
Number of subjects: 0
Study 15021280 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg intravenous bolus of dexamethasone
Number of subjects: 20
Study 15021280 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 20
Study 11266371 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat bran fiber (WBF) intervention
Number of subjects: 1287
Study 9650498 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandimmune Neoral
Number of subjects: 61
Study 9650498 — intervention group
Group type: COMPARATOR
Intervention: Sandimmune
Number of subjects: 61
Study 8504633 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood flow to forearm and calf muscles
Number of subjects: 5
Study 8504633 — intervention group
Group type: EXPERIMENTAL
Intervention: Forearm blood flow
Number of subjects: 5
Study 8504633 — intervention group
Group type: EXPERIMENTAL
Intervention: Calf blood flow
Number of subjects: 5
Study 8504633 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood flow to forearm skin
Number of subjects: 5
Study 8504633 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood flow to forearm adipose tissue
Number of subjects: 5
Study 3440615 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration of the elbow and instillation of local anaesthetic
Number of subjects: 80
Study 3440615 — intervention group
Group type: EXPERIMENTAL
Intervention: Early active movement encouraged
Number of subjects: 80
Study 3440615 — intervention group
Group type: COMPARATOR
Intervention: Retrospective controls (delayed active movement)
Number of subjects: 80
Study 29409469 — intervention group
Group type: EXPERIMENTAL
Intervention: Active surveillance
Number of subjects: 300
Study 29409469 — intervention group
Group type: COMPARATOR
Intervention: Standard oesophagectomy
Number of subjects: 300
Study 27210780 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastro-Laryngeal Tube (GLT)
Number of subjects: 80
Study 26508448 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutting balloon angioplasty
Number of subjects: 39
Study 26508448 — intervention group
Group type: COMPARATOR
Intervention: High-pressure balloon angioplasty
Number of subjects: 39
Study 23687222 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir for 7 or 21 days
Number of subjects: 301
Study 23687222 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir for 7 or 21 days
Number of subjects: 301
Study 23687222 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine/zidovudine for 7 or 21 days
Number of subjects: 301
Study 23687222 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2B6 983T → C genotype
Number of subjects: 301
Study 23687222 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2B6 516G → T genotype
Number of subjects: 301
Study 23687222 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergent resistance
Number of subjects: 301
Study 20502415 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers (ARBs)
Number of subjects: 188
Study 20502415 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (CCBs)
Number of subjects: 188
Study 20502415 — intervention group
Group type: COMPARATOR
Intervention: High-dose CCB (group C)
Number of subjects: 188
Study 20502415 — intervention group
Group type: COMPARATOR
Intervention: High-dose ARB (group D)
Number of subjects: 188
Study 20502415 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose combination therapy (CCB plus ARB, group E)
Number of subjects: 188
Study 18426826 — intervention group
Group type: EXPERIMENTAL
Intervention: I131 treatment
Number of subjects: 40
Study 18426826 — intervention group
Group type: COMPARATOR
Intervention: Control (no I131 treatment)
Number of subjects: 40
Study 16796484 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Intervention
Number of subjects: 236
Study 16796484 — intervention group
Group type: COMPARATOR
Intervention: Minimum Intervention
Number of subjects: 236
Study 12865039 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondihydropyridine CCB (verapamil SR 240 mg/day)
Number of subjects: 1209
Study 12865039 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor (trandolapril 2 mg/day)
Number of subjects: 1209
Study 12865039 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of verapamil SR (180 mg/day) plus trandolapril (2 mg/day)
Number of subjects: 1209
Study 12865039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1209
Study 12865039 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril (2 mg/day)
Number of subjects: 1209
Study 12865039 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil SR (180 mg/day) plus trandolapril (2 mg/day)
Number of subjects: 1209
Study 10402686 — intervention group
Group type: EXPERIMENTAL
Intervention: OCD group
Number of subjects: 40
Study 10402686 — intervention group
Group type: COMPARATOR
Intervention: Anxious controls
Number of subjects: 40
Study 10402686 — intervention group
Group type: COMPARATOR
Intervention: Undergraduate students
Number of subjects: 40
Study 7487856 — intervention group
Group type: EXPERIMENTAL
Intervention: One session therapist‐directed exposure (maximum 3 hours)
Number of subjects: 52
Study 7487856 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific manual‐based treatment at the clinic
Number of subjects: 52
Study 7487856 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific manual‐based treatment in the home
Number of subjects: 52
Study 7487856 — intervention group
Group type: EXPERIMENTAL
Intervention: General manual‐based treatment in the home
Number of subjects: 52
Study 7487856 — intervention group
Group type: EXPERIMENTAL
Intervention: General manual‐based treatment at the clinic
Number of subjects: 52
Study 2303015 — intervention group
Group type: EXPERIMENTAL
Intervention: Sepulveda Epilepsy Education program (SEE)
Number of subjects: 38
Study 6996620 — intervention group
Group type: EXPERIMENTAL
Intervention: FPL 52758 (10 microgram, i.d. injection)
Number of subjects: 20
Study 6996620 — intervention group
Group type: EXPERIMENTAL
Intervention: FPL 52758 (1.5 mg, topical application under occlusion for 24 hours)
Number of subjects: 20
Study 6996620 — intervention group
Group type: COMPARATOR
Intervention: FPL 57787 (5% ointment)
Number of subjects: 20
Study 29580592 — intervention group
Group type: EXPERIMENTAL
Intervention: Palpation method for ETTc inflation
Number of subjects: 139
Study 29580592 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum occlusive volume technique for ETTc inflation
Number of subjects: 139
Study 29580592 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum leak technique for ETTc inflation
Number of subjects: 139
Study 29580592 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-return back into the syringe method for ETTc inflation
Number of subjects: 139
Study 27894306 — intervention group
Group type: EXPERIMENTAL
Intervention: Killed whole-HIV vaccine, SAV001
Number of subjects: 33
Study 27894306 — intervention group
Group type: EXPERIMENTAL
Intervention: Killed whole-HIV vaccine, SAV001 with adjuvant
Number of subjects: 33
Study 27894306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 25171042 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) combined with demineralized freeze-dried bone allograft (DFDBA)
Number of subjects: 24
Study 25171042 — intervention group
Group type: COMPARATOR
Intervention: DFDBA with saline
Number of subjects: 24
Study 24474097 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactic acid (85%) + sunscreen
Number of subjects: 27
Study 24474097 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycolic acid (70%) + sunscreen
Number of subjects: 27
Study 24474097 — intervention group
Group type: COMPARATOR
Intervention: Control group (sunscreen only)
Number of subjects: 27
Study 19875684 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg sildenafil
Number of subjects: 20
Study 19133945 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive, preventive‐based, non‐invasive management of dental caries
Number of subjects: 902
Study 19133945 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard management of dental caries)
Number of subjects: 902
Study 16418408 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day triple therapy (20 mg of rabeprazole, 500 mg of clarithromycin, and 1 g of amoxicillin)
Number of subjects: 156
Study 16418408 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day sequential regimen (20 mg of rabeprazole plus 1 g of amoxicillin for 5 days and 20 mg of rabeprazole, 500 mg of clarithromycin, and 500 mg of tinidazole for the remaining 5 days)
Number of subjects: 156
Study 16418408 — intervention group
Group type: COMPARATOR
Intervention: 10-day sequential regimen
Number of subjects: 156
Study 12831223 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass polyphosphonate cement (Diamond)
Number of subjects: 31
Study 12831223 — intervention group
Group type: COMPARATOR
Intervention: Glass polyalkenoate cement (Ketac‐Cem)
Number of subjects: 31
Study 10594394 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate 15 mg/week
Number of subjects: 32
Study 10594394 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate 25 mg/week
Number of subjects: 32
Study 10594394 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate dose escalation from 15 to 25 mg/week
Number of subjects: 32
Study 8686833 — intervention group
Group type: EXPERIMENTAL
Intervention: pethidine 25 mg (1 ml)
Number of subjects: 150
Study 8686833 — intervention group
Group type: EXPERIMENTAL
Intervention: lignocaine 10 mg (1 ml)
Number of subjects: 150
Study 8686833 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (1 ml)
Number of subjects: 150
Study 1776542 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior therapy plus cognitive therapy (BT + CT)
Number of subjects: 69
Study 1776542 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior therapy plus nutrition education (BT + NE)
Number of subjects: 69
Study 1776542 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior therapy plus cognitive therapy and nutrition education (BT + CT + NE)
Number of subjects: 69
Study 1776542 — intervention group
Group type: COMPARATOR
Intervention: Behavior therapy plus social support (BT)
Number of subjects: 69
Study 1776542 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 69
Study 1776542 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive groups
Number of subjects: 69
Study 1776542 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition intervention
Number of subjects: 69
Study 7315774 — intervention group
Group type: EXPERIMENTAL
Intervention: Beef diet (one egg and at least 5 oz of beef daily for 3 months)
Number of subjects: 129
Study 7315774 — intervention group
Group type: EXPERIMENTAL
Intervention: Poultry and fish diet (one egg and at least 5 oz of poultry and fish daily for 3 months)
Number of subjects: 129
Study 3882217 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (doxorubicin ≤ 550 mg/m2, cyclophosphamide ≤ 5500 mg/m2, methotrexate ≤ 1000 mg/kg)
Number of subjects: 31
Study 3882217 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 31
Study 3882217 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 31
Study 31067122 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-exposure prophylaxis (PrEP) adherence measured by intracellular tenofovir-diphosphate (TFV-DP) levels
Number of subjects: 313
Study 31067122 — intervention group
Group type: EXPERIMENTAL
Intervention: Partnership type (no/single, single+, multi)
Number of subjects: 313
Study 31067122 — intervention group
Group type: EXPERIMENTAL
Intervention: mCalcR Score (risk assessment)
Number of subjects: 313
Study 31067122 — intervention group
Group type: EXPERIMENTAL
Intervention: Partnership type change
Number of subjects: 313
Study 29633367 — intervention group
Group type: EXPERIMENTAL
Intervention: CL + PDT
Number of subjects: 15
Study 29633367 — intervention group
Group type: EXPERIMENTAL
Intervention: FL + PDT
Number of subjects: 15
Study 27897610 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (1,000 IU daily for 6 weeks)
Number of subjects: 36
Study 27897610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 23989533 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecadenoson (75, 150, or 300 μg intravenous)
Number of subjects: 21
Study 23989533 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (100 μg/kg/min for 10 min then 50 μg/kg/min for 50 min)
Number of subjects: 21
Study 23989533 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Tecadenoson and Esmolol
Number of subjects: 21
Study 23025048 — intervention group
Group type: EXPERIMENTAL
Intervention: Emoxipin (single dose, 150 mg)
Number of subjects: 0
Study 23025048 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexidol (single dose, 300 mg)
Number of subjects: 0
Study 23025048 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamberin (single dose, 400 ml 1.5% solution)
Number of subjects: 0
Study 20306537 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 200
Study 18634953 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin-A
Number of subjects: 24
Study 18634953 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 24
Study 15678536 — intervention group
Group type: EXPERIMENTAL
Intervention: Spin-echo EPI at 3 T
Number of subjects: 0
Study 15678536 — intervention group
Group type: EXPERIMENTAL
Intervention: Low threshold to identify activated voxels
Number of subjects: 0
Study 11802037 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal azelastine (two puffs twice a day, 548 microg/d for 2 weeks)
Number of subjects: 20
Study 11802037 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal azelastine
Number of subjects: 20
Study 11802037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10391281 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump surgery
Number of subjects: 32
Study 10391281 — intervention group
Group type: COMPARATOR
Intervention: Cardiopulmonary bypass (CPB)
Number of subjects: 32
Study 10391281 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump surgery with arterial and vein grafts
Number of subjects: 32
Study 10391281 — intervention group
Group type: COMPARATOR
Intervention: CPB group
Number of subjects: 32
Study 8631089 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms recombinant DNA vaccinia vaccines against hepatitis B; administered at newborn, 1 month, and 6 months.
Number of subjects: 142